Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

withdrawn150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruiting

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

NCT04090034
withdrawnphase_2

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

NCT04713202

Clinical Trials (2)

Showing 2 of 2 trials
NCT04090034

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Recruiting
NCT04713202Phase 2

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

Withdrawn

All 2 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
2